Isomorphic Labs AlphaFold 3 Role Record

Isomorphic Labs AlphaFold 3 Role Record

Isomorphic Labs describes its work as applying AI to drug design. The AlphaFold 3 paper and the May 2024 company launch page identify it as a co-developer with Google DeepMind.

That record corrects the E016 outline's ownership simplification. Reviewed sources do not establish that Isomorphic Labs solely owned AlphaFold 3 intellectual property. They establish a joint development role and the company's use of the model within its drug-design work.

Isomorphic Labs' current site goes beyond AlphaFold 3 and presents a broader drug-design engine. Those 2026 claims are current company framing and should not be projected backward into the May 2024 episode.

The company has described collaborations, investment, leadership changes, and research progress since E016. Those facts belong in the maintained [[Isomorphic Labs Company Profile]]. The local E016 record owns only the dated AlphaFold 3 role and the boundary between research capability, company ambition, and demonstrated drug outcomes.

Company statements about speed, accuracy, transformed discovery, or future therapies require their cited evidence and qualified scientific review. A structural prediction can inform a hypothesis without proving that a candidate is safe, effective, manufacturable, or clinically successful.